(LYMPHIR) is set to begin selling this quarter – exciting times ahead! It's hard to believe that a Phase 3 FDA-approved stock with a market cap of only a few million dollars even exists. This situation is almost unbelievable.
This stock is set for a massive move. It's the best bargain and super undervalued. There is no offering, no dilute, and a 5.9 million share float. The chart looks poised for a breakout $2.00. This will fly soon! It’s a matter of time, Bullish.
Lymphir is the only CTCL therapy that targets the interleukin-2 (IL-2) receptor found on malignant T-cells and Tregs. This is the first indication for Lymphir and Citius Pharma’s first FDA-approved product.
Citius Pharmaceuticals (CTXR), the parent company, owns 92% of the outstanding shares of CTOR, and it also owns Mino-Lok.
Mino-Lok (For Cancer and Infection Prevention) Successful Phase 3 Clinical Trial of Mino-Lok®. Mino-Lok® is on a pathway to a New Drug Application (NDA) submission
News 
Market Data 
Markets 
AI
